GlassScriptPhysician profile
Roueen Rafeyan
NPI 1003891458
$2,357,298.96
in general payments reported to CMS, 2019-2025
37 companies · $402K in 2025
The $402K reported for 2025 was more than what 99% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
See the full distribution for Addiction Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368K · 2020: $154K · 2021: $285K · 2022: $350K · 2023: $430K · 2024: $369K · 2025: $402K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $921K · Consulting Fee: $129K · Travel and Lodging: $100K · Food and Beverage: $33K · Honoraria: $16K · Gift: $1,414 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $920,786.00 |
| Consulting Fee | $129,229.75 |
| Travel and Lodging | $100,410.99 |
| Food and Beverage | $33,002.39 |
| Honoraria | $15,525.00 |
| Gift | $1,413.84 |
| Education | $108.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $436,274.66 | 2020-2025 | Caplyta |
| Alkermes, INC. | $409,890.21 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $406,480.30 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $357,002.52 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $275,385.37 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $87,278.74 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $86,987.83 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $70,056.56 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $64,191.67 | 2019-2025 | Invega Trinza, Invega Sustenna, Spravato |
| H. Lundbeck A S | $55,441.31 | 2019-2022 | |
| Abbvie INC. | $50,547.08 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $17,304.36 | 2020-2025 | Fanapt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15,670.85 | 2019-2022 | |
| Allergan, INC. | $14,733.89 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $5,567.84 | 2019-2024 | Trintellix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $1,757.81 | 2021-2023 | Zimhi, Lucemyra |
| Lundbeck LLC | $1,701.93 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Bausch Health US, LLC | $345.26 | 2020-2025 | Wellbutrin, Aplenzin |
| Indivior INC. | $121.18 | 2022-2024 | Perseris, Sublocade |
| Idorsia Pharmaceuticals US INC | $111.16 | 2023-2024 | Quviviq |
| Neuronetics, INC. | $106.84 | 2019 | |
| Noven Therapeutics, LLC | $80.88 | 2020-2025 | Xelstrym, Secuado |
| Supernus Pharmaceuticals, INC. | $80.07 | 2023 | Qelbree |
| Jazz Pharmaceuticals INC. | $71.93 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $28.24 | 2024 | Nuplazid |
| Shire North American Group INC | $21.61 | 2019 | |
| Orexo US, INC. | $21.18 | 2019 | |
| Mdd US Operations, LLC | $20.33 | 2019 | |
| Noven Pharmaceuticals, INC. | $13.77 | 2022 | |
| Corium, LLC | $3.58 | 2025 | Azstarys |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roueen Rafeyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.